

Vidac Pharma Secures U.S. Patent Protection for Mitochondria-Targeted Cancer Therapy

USPTO Grants Notice of Allowance for Patent Claims Covering Vidacs Innovative HK2-Detaching Compounds Designed to Restore Mitochondrial Function in Cancer Cells

LONDON, UNITED KINGDOM,
September 30, 2025 /

EINPresswire.com/ -- Vidac Pharma Holdings Plc., a clinical-stage oncology biopharmaceutical company pioneering a new approach to cancer

treatment by reactivating mitochondrial health, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application No. 17/583,238, covering its proprietary class of HK2/mitochondria-detaching small molecule compounds.



“

our approach addresses the root metabolic defect in HK2-expressing tumors by restoring normal mitochondrial control”

Dr. Max Herzberg

The allowed claims (1–16) broadly protect Vidac’s platform technology, encompassing multiple chemical families, pharmaceutical compositions containing these compounds, and therapeutic methods aimed at restoring mitochondrial function by detaching Hexokinase 2 (HK2) from mitochondrial pores — a key metabolic checkpoint hijacked by cancer cells to fuel uncontrolled growth, better known as the “Warburg Effect.”

By “curing” the mitochondria, Vidac’s compounds renormalize tumor cell metabolism and selectively drive cancer cells toward programmed cell death, sparing surrounding healthy tissue. This milestone reinforces Vidac’s pioneering role in the rapidly evolving field of metabolism-based cancer therapies.

Dr. Max Herzberg, CEO of Vidac Pharma, stated:

“This allowance secures foundational protection for our mitochondria-targeting strategy, which we believe has the potential to transform cancer care. Unlike conventional therapies, our

approach addresses the root metabolic defect in HK2-expressing tumors by restoring normal mitochondrial control. This recognition from the USPTO is a critical step in advancing our vision of delivering breakthrough treatments to patients worldwide."

Max Herzberg
Vidac pharma Holding Plc
+972 54-425-7381
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/853991772>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.